News

Article

Sanofi and Seagen Announce ADC Development Collaboration

Sanofi and Seagen have entered an agreement to investigate three cancer targets.

Sanofi and Seagen announced on March 16, 2022, an exclusive collaboration agreement to design, develop, and commercialize novel antibody-drug conjugates (ADCs). The companies will use Sanofi’s monoclonal antibody technology and Seagen’s ADC technology to investigate up to three cancer targets.

“This collaboration will enable the synergistic combination of molecules and platforms to produce candidate medicines with the potential of bringing renewed hope to cancer patients and their families,” said John Reed, global head of R&D, Sanofi, in a company press release. “We look forward to joining forces with Seagen to collaboratively design and develop promising medicines by advancing antibody-drug conjugate science.”

“We are excited to be working with Sanofi, a global biopharmaceutical leader, to identify new ways to potentially address unmet medical needs of cancer patients,” said Clay Siegall, president and CEO, Seagen, in the press release. “Jointly developing novel ADCs by combining antibodies from Sanofi with Seagen’s proprietary ADC technology, aligns with our strategic priorities to expand the global potential of our pipeline with new first- or best-in-class programs.”

Per the terms of the agreement, the companies will co-fund global development and equally share any resulting profits. Additionally, Sanofi will make an undisclosed payment to Seagen for each of the three targets as they are selected. According to the press release, Sanofi has already selected the first target.

Source: Sanofi

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content